• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性高草酸尿症的诊断和治疗:最佳实践。

Diagnosis and management of primary hyperoxalurias: best practices.

机构信息

Division of Pediatric Nephrology, Baylor College of Medicine, Texas Children's Hospital, Houston, USA.

Division of Pediatric Nephrology, Hospital for Sick Children, University of Toronto, Toronto, Canada.

出版信息

Pediatr Nephrol. 2024 Nov;39(11):3143-3155. doi: 10.1007/s00467-024-06328-2. Epub 2024 May 16.

DOI:10.1007/s00467-024-06328-2
PMID:38753085
Abstract

The primary hyperoxalurias (PH 1, 2, and 3) are rare autosomal recessive disorders of glyoxylate metabolism resulting in hepatic overproduction of oxalate. Clinical presentations that should prompt consideration of PH include kidney stones, nephrocalcinosis, and kidney failure of unknown etiology, especially with echogenic kidneys on ultrasound. PH1 is the most common and severe of the primary hyperoxalurias with a high incidence of kidney failure as early as infancy. Until the recent availability of a novel RNA interference (RNAi) agent, PH care was largely supportive of eventual need for kidney/liver transplantation in PH1 and PH2. Together with the Oxalosis and Hyperoxaluria Foundation, the authors developed a diagnostic algorithm for PH1 and in this report outline best clinical practices related to its early diagnosis, supportive treatment, and long-term management, including the use of the novel RNAi. PH1-focused approaches to dialysis and kidney/liver transplantation for PH patients with progression to chronic kidney disease/kidney failure and systemic oxalosis are suggested. Therapeutic advances for this devastating disease heighten the importance of early diagnosis and informed treatment.

摘要

原发性高草酸尿症(PH1、2 和 3)是一种罕见的常染色体隐性遗传性乙醛酸代谢紊乱,导致肝脏草酸过度生成。应促使考虑 PH 的临床表现包括肾结石、肾钙质沉着症和原因不明的肾衰竭,尤其是在超声检查中显示肾脏回声增强。PH1 是原发性高草酸尿症中最常见和最严重的一种,婴儿期就有很高的肾衰竭发生率。直到最近新型 RNA 干扰 (RNAi) 药物的出现,PH1 和 PH2 的治疗主要是支持最终需要进行肾/肝移植。作者与草酸和高草酸尿症基金会一起,为 PH1 开发了一种诊断算法,并在此报告中概述了与早期诊断、支持性治疗和长期管理相关的最佳临床实践,包括新型 RNAi 的使用。对于进展为慢性肾脏病/肾衰竭和全身性草酸过多症的 PH 患者,建议采用针对 PH1 的透析和肾/肝移植方法。针对这种破坏性疾病的治疗进展提高了早期诊断和知情治疗的重要性。

相似文献

1
Diagnosis and management of primary hyperoxalurias: best practices.原发性高草酸尿症的诊断和治疗:最佳实践。
Pediatr Nephrol. 2024 Nov;39(11):3143-3155. doi: 10.1007/s00467-024-06328-2. Epub 2024 May 16.
2
Primary Hyperoxaluria Type 11型原发性高草酸尿症
3
The primary hyperoxalurias.原发性高草酸尿症
Kidney Int. 2009 Jun;75(12):1264-1271. doi: 10.1038/ki.2009.32. Epub 2009 Feb 18.
4
[Primary hyperoxaluria: A review].[原发性高草酸尿症:综述]
Nephrol Ther. 2016 Nov;12(6):431-436. doi: 10.1016/j.nephro.2016.03.005. Epub 2016 Jun 29.
5
The primary hyperoxalurias.原发性高草酸尿症
Semin Nephrol. 2008 Mar;28(2):152-62. doi: 10.1016/j.semnephrol.2008.01.008.
6
The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria.遗传检测在单基因肾结石病中的作用不断演变:原发性高草酸尿症聚焦。
J Urol. 2024 Nov;212(5):649-659. doi: 10.1097/JU.0000000000004147. Epub 2024 Aug 2.
7
An update on primary hyperoxaluria.原发性高草酸尿症的最新进展。
Nat Rev Nephrol. 2012 Jun 12;8(8):467-75. doi: 10.1038/nrneph.2012.113.
8
Recent advances in the identification and management of inherited hyperoxalurias.遗传性高草酸尿症的鉴定和管理的最新进展。
Urolithiasis. 2019 Feb;47(1):79-89. doi: 10.1007/s00240-018-1093-3. Epub 2018 Dec 10.
9
Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome.儿童 1 型原发性高草酸尿症:临床和实验室表现及结局。
Pediatr Nephrol. 2023 Aug;38(8):2643-2648. doi: 10.1007/s00467-023-05917-x. Epub 2023 Mar 14.
10
Clinical spectrum of primary hyperoxaluria type 1: Experience of a tertiary center.1型原发性高草酸尿症的临床谱:一家三级中心的经验
Nephrol Ther. 2017 May;13(3):176-182. doi: 10.1016/j.nephro.2016.08.002. Epub 2017 Feb 1.

引用本文的文献

1
Sweeteners: erythritol, xylitol and cardiovascular risk-friend or foe?甜味剂:赤藓糖醇、木糖醇与心血管风险——是友还是敌?
Cardiovasc Res. 2025 Aug 14;121(9):1319-1329. doi: 10.1093/cvr/cvaf091.
2
Synthesis and LDHA Inhibitory Activity of New Stiripentol-Related Compounds of Potential Use in Primary Hyperoxaluria.用于原发性高草酸尿症的新型司替戊醇相关化合物的合成及乳酸脱氢酶A抑制活性
Int J Mol Sci. 2024 Dec 10;25(24):13266. doi: 10.3390/ijms252413266.
3
Effect of the allelic background on the phenotype of primary hyperoxaluria type I.等位基因背景对I型原发性高草酸尿症表型的影响。

本文引用的文献

1
A Case Report of Kidney-Only Transplantation in Primary Hyperoxaluria Type 1: A Novel Approach with the Use of Nedosiran.1型原发性高草酸尿症单纯肾移植病例报告:使用尼多司坦的新方法
Case Rep Nephrol Dial. 2023 Jul 7;13(1):63-69. doi: 10.1159/000531053. eCollection 2023 Jan-Dec.
2
Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi?在接受 RNAi 治疗的原发性高草酸尿症儿童中,是否可以停止夜间过度水化?
J Nephrol. 2023 Jun;36(5):1473-1476. doi: 10.1007/s40620-023-01611-1. Epub 2023 May 20.
3
Correction to: Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I.
Curr Opin Nephrol Hypertens. 2025 Mar 1;34(2):177-183. doi: 10.1097/MNH.0000000000001057. Epub 2024 Dec 6.
4
Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.原发性和肠道高草酸尿症在临床与实验室之间交叉路口的机遇
Kidney Int Rep. 2024 Sep 1;9(11):3083-3096. doi: 10.1016/j.ekir.2024.08.031. eCollection 2024 Nov.
对《3 特斯拉磁共振成像检测 I 型原发性高草酸尿症患者的草酸盐骨病》一文的更正
Pediatr Nephrol. 2023 Jul;38(7):2497-2498. doi: 10.1007/s00467-022-05868-9.
4
Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I.三特斯拉磁共振成像检测Ⅰ型原发性高草酸尿症患者的草酸钙骨病。
Pediatr Nephrol. 2023 Jul;38(7):2083-2092. doi: 10.1007/s00467-022-05836-3. Epub 2022 Dec 6.
5
Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases.鲁马西拉治疗下的1型原发性高草酸尿症孤立肾移植:5例报告
Nephrol Dial Transplant. 2023 Feb 13;38(2):517-521. doi: 10.1093/ndt/gfac295.
6
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.Lumasiran 治疗 1 型原发性高草酸尿症婴儿和幼儿的疗效和安全性:III 期 ILLUMINATE-B 试验的 12 个月分析。
Pediatr Nephrol. 2023 Apr;38(4):1075-1086. doi: 10.1007/s00467-022-05684-1. Epub 2022 Aug 1.
7
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.用于 1 型原发性高草酸尿症的卢马昔兰:III 期 ILLUMINATE-C 试验。
Am J Kidney Dis. 2023 Feb;81(2):145-155.e1. doi: 10.1053/j.ajkd.2022.05.012. Epub 2022 Jul 14.
8
Genetic assessment in primary hyperoxaluria: why it matters.原发性高草酸尿症的遗传评估:为何重要。
Pediatr Nephrol. 2023 Mar;38(3):625-634. doi: 10.1007/s00467-022-05613-2. Epub 2022 Jun 13.
9
Treatment of primary hyperoxaluria type 1.1型原发性高草酸尿症的治疗
Clin Kidney J. 2022 May 17;15(Suppl 1):i9-i13. doi: 10.1093/ckj/sfab232. eCollection 2022 May.
10
Primary hyperoxaluria type 1: pathophysiology and genetics.1型原发性高草酸尿症:病理生理学与遗传学
Clin Kidney J. 2022 May 17;15(Suppl 1):i4-i8. doi: 10.1093/ckj/sfab217. eCollection 2022 May.